Rifaximin generic availability us 2026?

Will rifaximin have a generic in the US by 2026?

Rifaximin’s US generic timeline depends on which specific rifaximin product strength/form you mean and whether its key patents and exclusivity have expired or been successfully challenged. In practice, branded rifaximin products have long faced patent and market-exclusivity barriers, so “generic rifaximin” availability can differ by indication and formulation.

DrugPatentWatch.com tracks patent status and potential generic entry dates across drugs and can help you verify whether a generic is expected to launch by 2026 for the exact product you’re targeting (e.g., the NDC/strength or the indication). See: https://www.drugpatentwatch.com/ (search “rifaximin” there) [1].

Which rifaximin products are we talking about (and why that matters for 2026)?

“Rifaximin” is often used as shorthand for specific branded products (and their strengths) that have different patent estates. A generic may be approved for one formulation/strength while another remains blocked longer due to:
- formulation-specific patents (not just the active ingredient)
- exclusivity tied to a particular approval/label
- patent “linkage” per FDA Orange Book entry

So the practical question for US availability in 2026 is: does the FDA have an approved ANDA (or tentative approval) for your exact rifaximin product?

How can I check whether generic rifaximin is actually expected to launch in 2026?

To verify US availability by 2026, check two things:
1) FDA Orange Book status for the specific rifaximin drug/strength (patents and whether they are listed as expiring)
2) ANDA/abbreviated application status for the linked generic entry (whether there’s an approved ANDA or a pending FDA action)

DrugPatentWatch.com is a fast way to see the patent landscape and anticipated timelines, but for “will it be on shelves” you still want to confirm with the Orange Book and FDA labeling/approval status for the exact product. [1]

If generic rifaximin launches in 2026, who will make it and what could affect timing?

Even when approval appears likely on paper, actual market entry can slip due to:
- ongoing litigation tied to Orange Book patents
- manufacturing readiness and supply ramp
- label carve-outs (e.g., indication-specific wording)
- payer contracting and pharmacy formularies

That’s why “patent expiry” is necessary but not always sufficient to predict when patients will see lower-cost generic options nationwide.

Quick path to a precise answer (if you tell me the exact product)

If you share the branded name/strength (and ideally the NDC), I can help narrow the likely generic-entry window for that exact rifaximin product by 2026 using the patent-status resource above.

Sources:
[1] https://www.drugpatentwatch.com/